The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Antimetastatic activity of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3): Final results of a phase I study in patients with advanced solid tumors.
Dirk Strumberg
No relevant relationships to disclose
Beate Schultheis
No relevant relationships to disclose
W Meyer-Sabellek
Employment or Leadership Position - Silence Therapeutics
C. Vank
Employment or Leadership Position - Silence Therapeutics
F Gebhardt
Employment or Leadership Position - Silence Therapeutics
A. Santel
Employment or Leadership Position - Silence Therapeutics
O. Keil
Employment or Leadership Position - Silence Therapeutics
K. Giese
Employment or Leadership Position - Silence Therapeutics
J. Kaufmann
Employment or Leadership Position - Silence Therapeutics
Joachim Drevs
No relevant relationships to disclose